A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

NCT01992653 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non Hodgkin

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Obinutuzumab
DRUG: Polatuzumab Vedotin
DRUG: Prednisolone
DRUG: Prednisone
DRUG: Rituximab

Sponsor

Genentech, Inc.